The real revolution came in 2012, when researchers Jennifer Doudna and Emmanuelle Charpentier harnessed CRISPR, a natural bacterial defense system. In bacteria, CRISPR cuts out invading viruses’ DNA ...

The discovery of the DNA structure sparked a flurry of new research, birthing fields like molecular biology, biotechnology, ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

From revolutionary CRISPR treatment to heavy drinking dangers, here's what you need to know about the latest health research.

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

Pioneering CRISPR trial shows single infusion permanently lowers bad cholesterol by 50% in patients who don't respond to medication.

The FDA previously placed two clinical studies on hold, including the Phase III trial in which the liver toxicity occurred. Intellia is working with experts to create a risk management program for nex ...

Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.

Explore CRISPR technology explained, gene editing science, DNA modification, and genetic engineering ethics—discover how ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...